secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001193125-22-276899
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio Q3 net loss $27.2M; cash $673.9M; NUV-868 Phase 1b on track
------------------------------------------------------------------------

- Net loss of $27.2M ($0.12/share) vs $22.0M ($0.11/share) in Q3 2021.
- Cash, cash equivalents and marketable securities of $673.9M as of Sep 30, 2022; runway through 2028.
- R&D expenses $21.3M (incl. $1.6M restructuring and $5.7M contract termination costs).
- Phase 1 monotherapy of NUV-868 dosing; Phase 1b combo with olaparib/enzalutamide expected by end of 2022.
- DDC platform first clinical candidate nomination on track for end of 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312522276899/0001193125-22-276899-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312522276899/d410431d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-276899

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer